Crystal Arthropathies
- Hyperuricemia Ups Risk for Non-Alcoholic Fatty Liver Disease
- Low-Dose Febuxostat vs Colchicine for Gout Flare Prevention
- COVID-19 Vaccination May Increase Gout Flares Among Patients With Infrequent Flares
- Ilaris Approval Expanded to Include Treatment of Gout Flares
- SGLT2 Inhibitors May Lower Risk for Recurrent Gout Flares, Early Mortality
- Proton Pump Inhibitor Use Linked With Gout Risk
- IL-1β-Targeted Therapy May Help Alleviate Gout Flares Among Patients Refractory to Standard Therapies
- Review Discusses Common Missteps in Treating Patients With Gout and CKD
- SGLT2 Inhibitors Lower the Risk for Gout Flares
- MTX and Pegloticase Cotherapy May Increase Long-Term Treatment-Response Rates Among Patients With Uncontrolled Gout
- Febuxostat Utilization Declines Following Label Change, Despite Favorable Benefit-Risk Profile
- Hyperuricemia, Gout Increase Heart Failure, Death Risk
Features
More Crystal Arthropathies features
Clinical Tools
Powered by
Powered by 
MORE CLINICAL TOOLS
